» Articles » PMID: 28415557

Long Non-coding RNA CTA Sensitizes Osteosarcoma Cells to Doxorubicin Through Inhibition of Autophagy

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Apr 19
PMID 28415557
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, several long non-coding RNAs (lncRNAs) have been implicated in osteosarcoma (OS). However, the regulatory roles of lncRNAs in chemotherapy resistance of OS still remain unclear. This study aimed to screen a novel lncRNA that contributes to chemotherapeutic resistance of OS, and to explore the underlying mechanisms. Our data showed that lncRNA CTA was markedly downregulated in OS tissues compared to their matched non-tumor tissues, and low expression of lncRNA CTA was significantly associated with the advanced clinical stage and tumor size. In addition, OS patients with low lncRNA CTA levels showed a worse prognosis when compared with those with high expression of lncRNA CTA. Furthermore, we report that lncRNA CTA has an inverse relationship with miR-210 expression in OS tissues. LncRNA CTA could be activated by doxorubicin (DOX), and could promote OS cell apoptosis by competitively binding miR-210, while inhibit cell autophagy. On the other hand, lncRNA CTA was downregulated in DOX-resistant OS cells. Overexpression of lncRNA CTA reduced autophagy and subsequently overcame DOX resistance of OS in vitro and in vivo. Therefore, we demonstrate that lncRNA CTA is an essential regulator in DOX-induced OS cell apoptosis, and the lncRNA CTA-miR-210 axis plays an important role in reducing OS chemoresistance.

Citing Articles

Regulating the regulators: long non-coding RNAs as autophagic controllers in chronic disease management.

Kumar A, Yap K, BharathwajChetty B, Lyu J, Hegde M, Abbas M J Biomed Sci. 2024; 31(1):105.

PMID: 39716252 PMC: 11667983. DOI: 10.1186/s12929-024-01092-9.


LncRNAs as potential prognosis/diagnosis markers and factors driving drug resistance of osteosarcoma, a review.

Hu S, Han X, Liu G, Wang S Front Endocrinol (Lausanne). 2024; 15:1415722.

PMID: 39015175 PMC: 11249743. DOI: 10.3389/fendo.2024.1415722.


H1Innovative approaches to combat anti-cancer drug resistance: Targeting lncRNA and autophagy.

Zhong C, Xie Z, Duan S Clin Transl Med. 2023; 13(10):e1445.

PMID: 37837401 PMC: 10576445. DOI: 10.1002/ctm2.1445.


Insights into the involvement of long non-coding RNAs in doxorubicin resistance of cancer.

Zhang H, Hu Y, Deng J, Fang G, Zeng Y Front Pharmacol. 2023; 14:1243934.

PMID: 37781691 PMC: 10540237. DOI: 10.3389/fphar.2023.1243934.


Long non-coding RNAs: controversial roles in drug resistance of solid tumors mediated by autophagy.

Saadh M, Almoyad M, Arellano M, Maaliw 3rd R, Castillo-Acobo R, Jalal S Cancer Chemother Pharmacol. 2023; 92(6):439-453.

PMID: 37768333 DOI: 10.1007/s00280-023-04582-z.


References
1.
Wang F, Xiong L, Huang X, Zhao T, Wu L, Liu Z . miR-210 suppresses BNIP3 to protect against the apoptosis of neural progenitor cells. Stem Cell Res. 2013; 11(1):657-67. DOI: 10.1016/j.scr.2013.04.005. View

2.
Li W, Xie P, Ruan W . Overexpression of lncRNA UCA1 promotes osteosarcoma progression and correlates with poor prognosis. J Bone Oncol. 2016; 5(2):80-5. PMC: 4908186. DOI: 10.1016/j.jbo.2016.05.003. View

3.
Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y . MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem. 2010; 286(1):420-8. PMC: 3013001. DOI: 10.1074/jbc.M110.170852. View

4.
Kai A, Chan L, Lo R, Lee J, Chak-Lui Wong C, Wong J . Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology. 2016; 64(2):473-87. PMC: 5074303. DOI: 10.1002/hep.28577. View

5.
Wang Z, Yin B, Wang B, Ma Z, Liu W, Lv G . MicroRNA-210 promotes proliferation and invasion of peripheral nerve sheath tumor cells targeting EFNA3. Oncol Res. 2014; 21(3):145-54. DOI: 10.3727/096504013X13841340689573. View